RTOG-0521 Page **1** of **4**

NRG Oncology/RTOG-0521 Data Dictionary NCTN/NCORP Data Archive Data Dictionary for NCT00288080-D1-Dataset.csv

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

In order to protect patient privacy, the two patients with grade 5 AEs have been grouped with patients who experienced a maximum grade of 4.

Causes of death for five patients who were excluded from the analysis did not undergo central review of cause of death.

The following inconsistencies with the manuscript exist:

• Number of patients lost to follow-up in the CONSORT diagram should be 10 in the AS+RT arm and 17 in the AS+RT+CT arm; the number of patients who withdrew consent should be 9 and 16, respectively.

#	Variable	Туре	Len	Description	Format/Coding for categorical data
1	study	Char	9	Study number	Character length 9
2	patid	Char	11	De-identified patient ID	Character length 11
3	include_in_analysis	Char	3	Indicator for inclusion in	Yes=Include in analysis
				analysis	No=Exclude from analysis
4	exclusion_reason	Char	60	Reason excluded from	Character, maximum length 60.
				analysis	Note: Blank for patients not excluded.
5	arm	Char	12	Assigned treatment arm	1=AS + RT
					2=AS + RT + CT
6	age	Num	8	Age at study entry (years)	Continuous
7	age_group	Num	8	Age at study entry, grouped	0= <65
					1= ≥65
8	race	Char	41	Race	Character, maximum length 41.
9	ethnicity	Char	22	Ethnicity	Character, maximum length 22
10	race_minority	Num	8	Race/ethnicity grouping	0=Non-hispanic white
					1=Hispanic or non-white
11	zubrod	Num	8	Zubrod performance status	0=Normal activity
				at study entry	1=Symptoms, but nearly fully ambulatory
					Note: Blank for 2 patients for whom Zubrod was not
					reported
12	gleason	Num	8	Gleason score at study entry	Gleason score at study entry
13	baseline_psa	Num	8	PSA at study entry (ng/dl)	Continuous

RTOG-0521 Page **2** of **4**

#	Variable	Туре	Len	Description	Format/Coding for categorical data
14	tstage	Char	2	T-stage at study entry (AJCC	T1= Clinically inapparent tumor neither palpable or
				Staging System, 6 th edition)	visible by imaging
					T2= Tumor confined within prostate
					T3=Tumor extends through prostate capsule
					T4=Tumor is fixed or invades adjacent structures
					other than seminal vesicles: bladder neck, external
					sphincter, rectum, levator muscles and/or pelvic
					wall
15	nstage_clinical	Char	3	N-Stage at study entry per	N0=No regional lymph node metastasis
				clinical assessment (AJCC	N1=Metastasis in regional lymph node(s)
				Staging System, 6 th edition)	NX=Regional lymph nodes cannot be assessed
					Unk=Clinical N-Stage not reported by site
16	nstage_path	Char	3	N-Stage at study entry per	pN0=No regional lymph node metastasis
				pathologic assessment (AJCC	pNX=Regional lymph nodes not sampled
				Staging System, 6 th edition)	Unk=Pathologic N-Stage not reported by site
17	mstage	Char	3	M-Stage at study entry (AJCC	M0=No distant metastasis
				Staging System, 6 th edition)	Unk=M-Stage not reported by site
18	risk_group	Char	37	Prostate cancer risk group	Character, maximum length 37
					Note: Blank for 6 patients whose gleason, PSA, and
					T-stage combination was not among the risk groups.
19	risk_group_model	Num	8	Prostate cancer risk group,	1=Gleason >= 9, PSA <= 150, any T-stage
				categorical	2=Gleason 8, PSA < 20, >= T2
					3=Gleason 8, PSA >= 20-150, any T-stage
					4=Gleason 7, PSA >= 20-150, any T-stage
					Note: Blank for 6 patients whose gleason, PSA, and
					T-stage combination was not among the risk groups.
20	received_rt	Char	3	Indicates whether patient	Yes=Received radiation therapy
				received radiation therapy	No=Did not receive radiation therapy
					Unk=Unknown – site did not report any data relating
					to radiation therapy delivery
21	no_rt_reason	Char	20	Reason for no radiation	Character, maximum length 20
				therapy	Note: Limited to patients where received_rt=No
22	rt_reviewed	Char	3	Radiation therapy	Yes=Radiation therapy reviewed
				compliance review status	No=Radiation therapy not reviewed
23	rt_delivery_review	Char	33	Radiation therapy protocol	Character, maximum length 33
_				compliance	
24	received_lhrh	Char	3	Indicates whether patient	Yes=Received LHRH agonist therapy
				received LHRH agonist	Unk=Unknown – site did not report any data relating
				therapy	to LHRH agonist therapy
25	received_ct	Char	3	Indicates whether patient	Received chemotherapy
				received chemotherapy	Note: Blank for patients on arm 1: AS+RT
26	ct_reviewed	Char	3	Chemotherapy protocol	Yes=Chemotherapy reviewed
				compliance review status	No=Chemotherapy not reviewed
					Note: Blank for patients on arm 1: AS+RT

RTOG-0521 Page **3** of **4**

#	Variable	Туре	Len	Description	Format/Coding for categorical data
27	ct_per_prot	Char	19	Chemotherapy protocol	Per protocol=Chemotherapy delivered per protocol
				compliance	requirements
					Not per protocol=Chemotherapy not delivered per
					protocol requirements
					Cannot be evaluated=Chemotherapy could not be
					evaluated due to missing data
					Note: Limited to patients where ct_reviewed=Yes
28	ct_delivery_delays	Char	23	Chemotherapy delays for per	No modifications/delays: Modifications/delays of
				protocol patients	chemotherapy were not needed.
					Modifications/delays: Modifications/delays of
					chemotherapy were needed.
					Not specified: Insufficient data to determine.
					Note: Limited to patients where ct_per_prot=Yes
29	oral_antiandrogen	Char	3	Indicates whether patient	Yes=Received oral antiandrogen therapy
				received oral antiandrogen	No=Did not receive oral antiandrogen therapy
				therapy	Unk=Unknown – site did not report any data relating
					to oral antiandrogen therapy
30	full_rx_sensitivity	Char	3	Full protocol treatment	Yes=Include in sensitivity analysis
				sensitivity analysis inclusion	No=Exclude from sensitivity analysis
				status	
31	max_ae_grade	Char	3	Maximum treatment-related	0=Grade 0,
				adverse event grade, graded	1=Grade 1,
				per CTCAE v3.0 criteria.	2=Grade 2,
					3=Grade 3,
					4 or 5=Grade 4 or 5
					Note: Blank for 1 patient who did not receive LHRH
					agonist, 1 patient whose LHRH status was unknown,
					and 4 patients for whom AE information was not
					reported.
32	max_ae_hem_grade	Num	8	Maximum treatment-related	0=Grade 0,
				hematologic adverse event	1=Grade 1,
				grade, graded per CTCAE	2=Grade 2,
				v3.0 criteria.	3=Grade 3,
					4=Grade 4
					Note: Blank for 1 patient who did not receive LHRH
					agonist, 1 patient whose LHRH status was unknown,
					and 4 patients for whom AE information was not
					reported.
33	survival	Num	8	Overall survival status	0=Alive(censored)
					1=Dead(event)
					Note: Blank for 6 patients for whom no follow-up
					data was submitted.

RTOG-0521 Page **4** of **4**

#	Variable	Туре	Len	Description	Format/Coding for categorical data
34	survival_years	Num	8	Time since randomization to	Continuous
				death/last follow-up (years)	Note: Blank for 6 patients for whom no follow-up
					data was submitted.
35	central_dss	Num	8	Centrally-reviewed disease-	0=Alive (censored)
				specific survival status	1=Death due to cancer under study (event)
					2=Dead due to other cause (competing risk)
					Note: Blank for 6 patients for whom no follow-up
					data was submitted.
36	cause_of_death	Char	18	Centrally-reviewed cause of	Character, maximum length 18
				death	Note: Limited to patients who were reported as dead
37	biochemical_failure	Num	8	Biochemical/PSA failure	0=Alive without failure (censored),
				status	1=PSA failure/initiation of non-protocol hormone
					therapy (event)
					2=Death without failure (competing risk)
					Note: Blank for 6 patients for whom no follow-up
					data was submitted.
38	biochemical_failure_year	Num	8	Biochemical/PSA failure time	Continuous
	S			since randomization (years)	Note: Blank for 6 patients for whom no follow-up
					data was submitted.
39	disease_free_survival	Num	8	Disease-free survival status	0=Alive without failure (censored),
					1=First of biochemical, local, or distant failure or
					death (event)
					Note: Blank for 6 patients for whom no follow-up
					data was submitted.
40	disease_free_survival_ye	Num	8	Disease-free survival time	Continuous
	ars			since randomization (years)	Note: Blank for 6 patients for whom no follow-up
					data was submitted.
41	any_distant_mets	Num	8	Distant metastasis failure	0=Alive without distant metastasis (censored)
				status	1=Distant metastasis (event)
					2=Death without distant metastasis (competing risk)
					Note: Blank for 6 patients for whom no follow-up
					data was submitted.
42	any_distant_mets_years	Num	8	Distant metastasis time since	Continuous
				randomization (years)	Note: Blank for 6 patients for whom no follow-up
40	Leaf to Calle	CI.		Land to Calle	data was submitted.
43	lost_to_followup	Char	3	Lost to follow-up status	Yes=Patient is lost to follow-up
		61			No=Patient is not lost to follow-up
44	lost_to_followup_reason	Char	51	Lost to follow-up reason	Reason lost to follow-up
					Note: Blank for patients not lost to follow-up